Doxycycline for Helicobacter Pylori Rescue Treatment
Doxycycline-containing Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: a Randomized Controlled Trial
Shanghai Jiao Tong University School of Medicine
368 participants
Jun 20, 2023
INTERVENTIONAL
Conditions
Summary
Current guidelines have recommended classical bismuth-containing quadruple therapy including proton-pump inhibitor, bismuth, tetracycline, metronidazole as the empirical rescue therapy. However, tetracycline is clinically unavailable in China and the high frequency of adverse events of bismuth quadruple therapy often result in poor compliance, which limited the applicability of this recommendation. This study aimed to compare the efficacy and tolerability of a 14-day bismuth-containing quadruple rescue therapy in which tetracycline was replaced by doxycycline.
Eligibility
Inclusion Criteria2
- Ability and willingness to participate in the study and to sign and give informed consent
- Confirmed H. pylori infection and with previous treatment failure
Exclusion Criteria6
- subjects naive to H. pylori treatment,
- under 18 or over 80 years old
- history of gastrectomy
- pregnant or lactating women
- severe systemic diseases or malignancy
- administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Proton pump inhibitor
Gastric mucosal protective drug with anti-H. pylori effect
Antibiotics for H. pylori eradication
Antibiotics for H. pylori eradication
Antibiotics for H. pylori eradication
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05874570